Biotechnology firm Photogen Technologies has reported a successful animal study of its PH-50 contrast agent technology, which may allow for visualization of soft plaque using CT, according to the New Hope, PA-based company.
In the study, white New Zealand rabbits were fed a high-cholesterol diet to promote the growth of vascular plaques. Several doses of PH-50, an iodinated nanoparticulate, were then administered intravenously.
CT scans were taken at multiple points after administration, and histology samples were taken from the plaque to confirm the test results. Nanoparticulate material observed by light microscopy in the atherosclerotic plaques of the heart was consistent with the infused test material, according to Photogen.
The company is planning further studies to investigate PH-50 and its utility in diagnosing vulnerable plaque in patients using standard CT systems.
March 19, 2002
Copyright © 2002 AuntMinnie.com
